Sperimentazioni cliniche

5-year multi center, observational post-authorization safety study to document the utilization of Wakix in the treatment of narcolepsy with or without cataplexy and to collect information on its long-term safety when used in routine medical practice. (15-11/PASS/WAKIX)

Postauthorization safety study to evaluate the risks of myelodysplastic syndrome/acute myeloid leukemia and second primary malignancies in adult patients with platinum-sensitive, relapsed, high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer receiving maintenance treatment with ZEJULA® (niraparib).

Studio di Fase III randomizzato per valutare l’efficacia e la sicurezza di Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + chemioterapia rispetto alla terapia standard come trattamento di prima linea in pazienti con carcinoma esofageo metastatico.

A Phase 3, Randomized Study to Evaluate the Efficacy and Safety of Pembrolizumab (MK-3475) + Lenvatinib (E7080/MK-7902) + Chemotherapy Compared with Standard of Care as First-line Intervention in Participants with Metastatic Esophageal Carcinoma.

Valutazione retrospettiva del “neutrophils-to-lymphocyte ratio” (NLR) in pazienti affetti da NSCLC in stadio localmente avanzato non operabili, sottoposti ad immunoterapia dopo trattamento radio-chemioterapico ad intento radicale nell’ambito dell’Expanded Access Program (EAP) Italia per il farmaco Durvalumab.

Maintenance with AVeLumAb in advanced urothelial neoplasms in response to first-line chemotherapy: an observational retrospective and prospective study (MALVA).

A Randomized, Open Label, Phase III Trial to Evaluate the Efficacy and Safety of Palbociclib + Anti- HER2 Therapy + Endocrine Therapy vs. Anti- HER2 Therapy + Endocrine Therapy after induction Treatment for Hormone Receptor Positive (HR+)/HER2- Positive Metastatic Breast Cancer. (AFT-38 PATINA)

Studio retrospettivo-prospettico osservazionale multicentrico sulla determinazione delle alterazioni molecolari nei pazienti con nuova diagnosi di carcinoma polmonare (ATLAS).

COMBI- APlus: OPEN-LABEL, phase IIIb study of dabrafenib in COMBInation with trametinib in the Adjuvant treatment of stage III BRAF V600 mutation-positive melanoma after complete resection to evaluate the impact on pyrexia related outcomes of an adapted pyrexia AE-management algorithm (Plus). Studio in aperto, di fase IIIb con Dabrafenib in COMBInazione con Trametinib nel trattamento Adiuvante del melanoma in studio III positivo per la mutazione BRAF V600 dopo resezione completa, per valutare l'impatto sugli esiti correlali alla piressia di un algoritmo per la gestione degli eventi avversi adattato alla piressia (Plus). (CDRB436F2410)

Studio di Fase II per valutare l'attività e la sicurezza di Cabozanitinib in pazienti già pretrattati con tumore polmonare non a piccole cellule (NSCLC) RET riarrangiati: studio CRETA.

Phase II study to evaluate the activity and safety of Cabozantinib in pretreated advanced RET-reArranged non-small cell lung cancer patients: CRETA trial.

A retrospective-prospective, multicenter, observational study aimed to record molecular data and to explore their correlations with clinical outcomes in gynecological cancer patients. The MITO GYNecological cancers GEnetic profile Registry (GYNGER) study.